OKYO Pharma Limited Ordinary Shares (OKYO) is a publicly traded Healthcare sector company. As of May 19, 2026, OKYO trades at $1.59 with a market cap of $82.39M and a P/E ratio of 0.00. OKYO moved +0.00% today. Year to date, OKYO is -28.70%; over the trailing twelve months it is +7.43%. Its 52-week range spans $0.90 to $3.35. Analyst consensus is buy with an average price target of $7.00. Rallies surfaces OKYO's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
OKYO Pharma Appoints MD PhD Expert, Secures Fast Track for 150-Patient Phase 2b/3: OKYO Pharma expanded its Scientific Advisory Board with Marta Sacchetti, MD, PhD, bolstering expertise in neuro-inflammatory corneal disease and targeted nerve regeneration. The company’s urcosimod holds the first IND for neuropathic corneal pain plus FDA Fast Track designation and will launch a 150-patient Phase 2b/3 study in H1 2026.
| Metric | Value |
|---|---|
| Price | $1.59 |
| Market Cap | $82.39M |
| P/E Ratio | 0.00 |
| EPS | $0.00 |
| Dividend Yield | 0.00% |
| 52-Week High | $3.35 |
| 52-Week Low | $0.90 |
| Volume | 11.05K |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $0 |
| Gross Margin | 0.00% |
1 analysts cover OKYO: 0 strong buy, 1 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $7.00.